NOTE 13 - SEGMENT INFORMATION

3 Months Ended

Jul. 31, 2020

Notes

NOTE 13 - SEGMENT INFORMATION

NOTE 13 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three months ended July 31, 2020 and 2019; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three months ended July 31, 2020 and 2019 is as follows: 

	Three Months Ended July 31,
	2020	2019
Revenues:
Stevioside - third party	$5,190,463	$4,527,666
Stevioside - related party	1,751,823	1,783,893
Total Stevioside	6,942,286	6,311,559
Corporate and other – third party	97,392	578,516
Corporate and other – related party	0	0
Total Corporate and other	97,392	578,516
Total segment and consolidated revenues	$7,039,678	$6,890,075
Interest expense:
Stevioside	$79,107	$180,444
Corporate and other	0	0
Total segment and consolidated interest expense	$79,107	$180,444
Depreciation and amortization:
Stevioside	$253,776	$199,222
Corporate and other	50,664	71,766
Total segment and consolidated depreciation and amortization	$304,440	$270,988
Income (loss) from continuing operations before income taxes:
Stevioside	$(1,064,253)	$(165,071)
Corporate and other	8,426	35,267
Total loss from continuing operations before income taxes	$(1,055,827)	$(129,804)

	July 31,2020	April 30,2020
Segment property and equipment:
Stevioside	$6,994,948	$6,976,153
Corporate and other	1,839,596	1,925,395
Total property and equipment	$8,834,544	$8,901,548